Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Saturday, December 15, 2018 · 471,226,275 Articles · 3+ Million Readers

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that management will present at two upcoming investor conferences in October:

  • 2018 Cantor Global Healthcare Conference at 9:10 a.m. ET on Tuesday, October 2, 2018 in New York City.
  • Leerink Partners Roundtable Series: Rare Disease & Oncology at 8:30 a.m. ET on Wednesday, October 3, 2018 in New York City.

Live webcasts of the presentations will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcasts, an archived replay will be available on the Company's website.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

/EIN News/ --

Fate Therapeutics.jpg

Powered by EIN News
Distribution channels: Conferences & Trade Fairs, Retail


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release